![]() Total revenues were $515 million in first-quarter 2023, a decrease of 21% compared to $652 million in first-quarter 2022. Refer to note (13) in the "Notes to the Reconciliations of GAAP and Non-GAAP Financial Measures" section below for additional discussion. Refer to the "Supplemental Financial Information" section below for reconciliations of certain non-GAAP financial measures to the most directly comparable GAAP financial measures.Įffective January 1, 2022, these non-GAAP financial measures now include acquired in-process research and development charges which were previously excluded under Endo's legacy non-GAAP policy. The information presented in the table above includes non-GAAP financial measures such as Adjusted Income from Continuing Operations, Adjusted Diluted Weighted Average Shares, Adjusted Diluted Net Income per Share from Continuing Operations and Adjusted EBITDA. In the case of Adjusted Diluted Weighted Average Shares, Adjusted Income from Continuing Operations is used in determining whether to include such dilutive impact. To read this article on click here.Reported Diluted Net Loss per Share from Continuing Operations is computed based on weighted average shares outstanding and, if there is income from continuing operations during the period, the dilutive impact of ordinary share equivalents outstanding during the period. ![]() Click to get this free reportĮndo International plc (ENDP) : Free Stock Analysis Reportīaudax Bio, Inc. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.īaudax Bio, Inc.'s revenues are expected to be $0.77 million, up 285% from the year-ago quarter. This company is expected to post quarterly loss of $1.27 per share in its upcoming report, which represents a year-over-year change of +82.7%. (BXRX), has yet to report results for the quarter ended June 2022. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Īnother stock from the same industry, Baudax Bio, Inc. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 36% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While Endo has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Įndo shares have lost about 82.2% since the beginning of the year versus the S&P 500's decline of -13.1%. The company has topped consensus revenue estimates four times over the last four quarters. This compares to year-ago revenues of $713.83 million. Over the last four quarters, the company has surpassed consensus EPS estimates four times.Įndo, which belongs to the Zacks Medical - Drugs industry, posted revenues of $569.11 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 9.01%. A quarter ago, it was expected that this health care company would post earnings of $0.44 per share when it actually produced earnings of $0.66, delivering a surprise of 50%. This quarterly report represents an earnings surprise of 118.75%. These figures are adjusted for non-recurring items. This compares to earnings of $0.65 per share a year ago. Endo International (ENDP) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |